---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-022718"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:14:17.598627+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adial signs exclusive AD04 collaboration framework with Molteni for Europe; potential $60M in milestones and royalties

## Summary
- Collaboration framework with Molteni Farmaceutici for exclusive AD04 commercialization in Europe; definitive agreement pending.
- Total potential aggregate value from royalties (high single to low double digits) and milestones estimated at nearly $60M.
- Molteni granted exclusivity for due diligence; upfront and milestone payments expected upon final agreement.
- AD04 is a genotype-driven Alcohol Use Disorder therapy; company also advancing US partner discussions.
- Special meeting on Feb 26 lacked quorum; company must call new meeting every 90 days until warrant approval.

## SEC filing metadata
- accession: 0001213900-26-022718
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/0001213900-26-022718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/ea0279472-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-022718
- JSON: https://secwatch.observer/filing/0001213900-26-022718.json
- Plain text: https://secwatch.observer/filing/0001213900-26-022718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.